Combinatorial efficacy of anti-CS1 monoclonal antibody elotuzumab (HuLuc63) and bortezomib against multiple myeloma

Monoclonal antibody (mAb) therapy for multiple myeloma, a malignancy of plasma cells, has not been clinically efficacious in part due to a lack of appropriate targets. We recently reported that the cell surface glycoprotein CS1 (CD2 subset 1, CRACC, SLAMF7, CD319), was highly and universally express...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: van Rhee, Frits, Szmania, Susann M., Dillon, Myles, van Abbema, Anne M., Li, Xin, Stone, Mary K., Garg, Tarun K, Shi, JuMei, Moreno-Bost, Amberly M., Yun, Rui, Balasa, Balaji, Ganguly, Bishwa, Chao, Debra, Rice, Audi G., Zhan, Fenghuang, Shaughnessy, John D., Barlogie, Bart, Yaccoby, Shmuel, Afar, Daniel E.H.
Format: Artigo
Idioma:Inglês
Publicat: 2009
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC2748787/
https://ncbi.nlm.nih.gov/pubmed/19723891
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1535-7163.MCT-09-0483
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars